$ALNY News

Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention

BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options

Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $340

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation

ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $375

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $300

Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $316